IMBRUVICA
140mgIMBRUVICA140mg
IMBRUVICA (ibrutinib) 140mg is a first-in-class BTK inhibitor revolutionizing treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and other B-cell malignancies.
Key Benefits
- First-in-class BTK inhibitor—pioneered targeted CLL therapy
- Chemotherapy-free treatment option
- Once-daily oral capsules—convenient home administration
- Highly effective in high-risk CLL with 17p deletion
- Significant survival benefits over chemotherapy
- Multiple hematologic malignancy indications
Contact Us for Pricing
Get competitive wholesale pricing for IMBRUVICA 140mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How IMBRUVICA Works
IMBRUVICA works by forming a covalent bond with BTK (Bruton's tyrosine kinase), irreversibly inhibiting its activity. BTK is a critical signaling molecule in the B-cell receptor (BCR) pathway, which promotes B-cell survival, proliferation, and migration to lymphoid tissues.
In CLL and other B-cell malignancies, the BCR pathway is often constitutively active, providing continuous survival signals to cancer cells. IMBRUVICA blocks this signaling, resulting in: 1. Inhibition of cancer cell proliferation 2. Induction of apoptosis (programmed cell death) 3. Mobilization of cancer cells from lymph nodes into the blood (transient lymphocytosis) 4. Disruption of the protective tumor microenvironment
The transient increase in blood lymphocyte count during the first weeks of treatment is a pharmacodynamic effect showing the drug is working—cancer cells are being flushed out of lymph nodes where they cannot survive.
About IMBRUVICA 140mg
IMBRUVICA (ibrutinib) 140mg by Pharmacyclics/Janssen is the groundbreaking first-in-class Bruton's tyrosine kinase (BTK) inhibitor that has transformed the treatment of B-cell malignancies. Since its approval, IMBRUVICA has become the standard of care for chronic lymphocytic leukemia (CLL), establishing a chemotherapy-free treatment paradigm. IMBRUVICA works by irreversibly inhibiting BTK, a crucial enzyme in the B-cell receptor signaling pathway that promotes cancer cell survival and proliferation. By blocking this pathway, IMBRUVICA drives cancer cells out of their protective lymph node microenvironment and promotes their death. Clinical trials have demonstrated remarkable efficacy—IMBRUVICA significantly improves progression-free survival and overall survival in CLL compared to chemotherapy-based regimens, with a more favorable tolerability profile. It is FDA-approved for CLL/SLL (including those with 17p deletion), mantle cell lymphoma, marginal zone lymphoma, Waldenström's macroglobulinemia, and chronic graft-versus-host disease. Pharmacy Remedy provides authentic Janssen IMBRUVICA capsules with international delivery for hematology centers, hospitals, and pharmaceutical distributors worldwide.
Common Uses
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Mantle cell lymphoma (MCL)
- Waldenström's macroglobulinemia
- Marginal zone lymphoma
- Chronic graft-versus-host disease
Dosage Information
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL):
Mantle Cell Lymphoma (MCL):
Waldenström's Macroglobulinemia:
Marginal Zone Lymphoma:
Chronic Graft-versus-Host Disease:
Administration:
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store IMBRUVICA capsules at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F and 86°F). Store in original container with desiccant. Keep container tightly closed.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About IMBRUVICA
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
